Equity Profile

PCVX

Vaxcyte, Inc.

Health CareBiotechnology$6.8B

May6Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Vaxcyte, Inc. Misses on EPS, Stock Up 2.62%

Metric	Actual	Expected	Surprise
EPS	$-2.30	$-1.77	-23.99%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Vaxcyte, Inc. Misses on EPS, Stock Up 2.62%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-2.30	$-1.77	-23.99%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Vaxcyte's earnings report shows a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, rising by 2.62%. This increase may reflect investor sentiment or optimism despite the disappointing EPS results.

Company Snapshot

Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to prevent infectious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health. Investors will be keen to see if Vaxcyte can narrow its losses this quarter.

-1.77

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to prevent infectious diseases. Operating in the healthcare sector, Vaxcyte aims to address significant public health challenges, making its innovations crucial in today's health landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In the last quarter, Vaxcyte reported an EPS of -5.63, significantly missing analyst expectations. The stock saw a modest increase of 1.81% the following day, indicating some investor optimism despite the disappointing results.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect continued losses for Vaxcyte, with a consensus EPS of -1.77. Investors will be closely watching for any signs of progress in the company's vaccine development pipeline.

Bull Case

If Vaxcyte can show improved clinical trial results or announce new partnerships, it could lead to a more favorable outlook and potentially drive the stock higher.

Bear Case

On the other hand, if the company fails to provide any positive updates or continues to miss earnings expectations, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

-1.77

Earnings per share is a key indicator of profitability and financial health. Investors will be keen to see if Vaxcyte can narrow its losses this quarter.

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Vaxcyte provide any updates on its vaccine pipeline or clinical trials?

Any positive news regarding vaccine development could significantly influence investor confidence and stock performance.

How does Vaxcyte plan to address its ongoing losses?

Investors will be looking for a clear strategy to improve financial performance, which could impact future valuations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Vaxcyte's potential for a turnaround, especially if there are positive developments in its vaccine pipeline that have not been fully priced in.

Supporting Evidence

The options market is pricing a 10.94% move, indicating expectations for significant volatility.

Vaxcyte's recent history of surprises suggests that it could outperform expectations if there are any positive updates.

Key Risk

If Vaxcyte announces a significant partnership or positive trial results, it could drastically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Vaxcyte's ability to control costs while advancing its vaccine development, making this quarter's results critical.

Bull Confirmed If

A narrower EPS loss of -1.50 or better would indicate progress in managing expenses and could boost investor confidence.

Bear Confirmed If

An EPS loss greater than -1.80 would reinforce concerns about the company's financial health and future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±10.94%

Historical Avg

±2.11%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that investors expect volatility based on the results.

Options price a 10.94% move but the stock has averaged only 2.11% over the last 8 quarters — setup is rich.

Detail

ATM IV

0.6%

30d HV

37.6%

Calls (14K)P/C Ratio: 6.71Puts (11K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 4 of 18 (22%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 18 (78%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.8%, with a raw directional average of +3.0% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations and provides positive updates, history suggests a potential stock increase of around 2.11% on the next trading day.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors digest the information and await further guidance.

Miss

If Vaxcyte misses expectations again, history suggests a potential decline of around 1.32%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial progress for Vaxcyte's vaccines.
2Management's strategy for reducing operational costs.
3Any new partnerships or collaborations that could enhance revenue potential.
4Insights into the timeline for product launches.
5Comments on market competition and how Vaxcyte plans to differentiate itself.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to prevent infectious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health. Investors will be keen to see if Vaxcyte can narrow its losses this quarter.

-1.77

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect continued losses for Vaxcyte, with a consensus EPS of -1.77. Investors will be closely watching for any signs of progress in the company's vaccine development pipeline.

Bull Case

If Vaxcyte can show improved clinical trial results or announce new partnerships, it could lead to a more favorable outlook and potentially drive the stock higher.

Bear Case

On the other hand, if the company fails to provide any positive updates or continues to miss earnings expectations, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

-1.77

Earnings per share is a key indicator of profitability and financial health. Investors will be keen to see if Vaxcyte can narrow its losses this quarter.

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Vaxcyte provide any updates on its vaccine pipeline or clinical trials?

Any positive news regarding vaccine development could significantly influence investor confidence and stock performance.

How does Vaxcyte plan to address its ongoing losses?

Investors will be looking for a clear strategy to improve financial performance, which could impact future valuations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Vaxcyte's potential for a turnaround, especially if there are positive developments in its vaccine pipeline that have not been fully priced in.

Supporting Evidence

The options market is pricing a 10.94% move, indicating expectations for significant volatility.

Vaxcyte's recent history of surprises suggests that it could outperform expectations if there are any positive updates.

Key Risk

If Vaxcyte announces a significant partnership or positive trial results, it could drastically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Vaxcyte's ability to control costs while advancing its vaccine development, making this quarter's results critical.

Bull Confirmed If

A narrower EPS loss of -1.50 or better would indicate progress in managing expenses and could boost investor confidence.

Bear Confirmed If

An EPS loss greater than -1.80 would reinforce concerns about the company's financial health and future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±10.94%

Historical Avg

±2.11%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that investors expect volatility based on the results.

Options price a 10.94% move but the stock has averaged only 2.11% over the last 8 quarters — setup is rich.

Detail

ATM IV

0.6%

30d HV

37.6%

Calls (14K)P/C Ratio: 6.71Puts (11K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 4 of 18 (22%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations and provides positive updates, history suggests a potential stock increase of around 2.11% on the next trading day.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors digest the information and await further guidance.

Miss

If Vaxcyte misses expectations again, history suggests a potential decline of around 1.32%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial progress for Vaxcyte's vaccines.
2Management's strategy for reducing operational costs.
3Any new partnerships or collaborations that could enhance revenue potential.
4Insights into the timeline for product launches.
5Comments on market competition and how Vaxcyte plans to differentiate itself.